AbbVie halts enrollment after brain cancer trial misses goal, shares fall

Shutterstock photo

May 17 (Reuters) - AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial.

The company's shares fell 1.8 percent to $78.10 before the bell.

An independent data monitoring committee recommended the study be stopped due to "lack of survival benefit" for patients receiving the treatment Depatux-M when compared with a placebo, AbbVie said.

The trial has been testing the drug to treat an aggressive form of brain cancer known as glioblastoma.

About 17,760 people are estimated to die from brain and spinal cord tumors in the United States, in 2019, according to the American Cancer Society.

This article appears in: World Markets , Stocks , Technology
Referenced Symbols: ABBV

More from Reuters


See Reuters News

Research Brokers before you trade

Want to trade FX?